3SBio Inc

Pfizer has entered a $1.25 billion licensing agreement with 3SBio Inc, a Chinese biotech firm, to acquire rights to an experimental cancer drug, marking a significant strategic alliance in the biopharmaceutical industry.

3SBio Inc. has secured a major licensing deal with Pfizer worth up to $6 billion, marking a significant milestone for the biotech company as it collaborates with the global pharmaceutical giant to advance a promising cancer drug.

3SBio Inc has announced a $1.25 billion partnership with Pfizer to develop and commercialize a promising cancer drug, marking a significant milestone for the biotechnology company.